Kingdomway (002626.SZ) subsidiary's Brazilian sweet protein product receives U.S. FDA GRAS no-objection letter

Zhitong Finance APP News, Kingdomway (002626.SZ) announced that recently, the company's wholly-owned subsidiary Inner Mongolia Kingdomway Pharmaceutical Co., Ltd. (hereinafter referred to as "Kingdomway Pharmaceutical") received a no-objection response letter from the U.S. Food and Drug Administration (FDA) for GRAS Notice No. GRN 001305. Kingdomway Pharmaceutical's Brazzein preparation product has completed the FDA GRAS notification evaluation, and the FDA issued a no-objection opinion on the GRAS (Generally Recognized as Safe) conclusion for the product under its declared use.